RxDoctor Payments Data

Cheta Nand, MD

Sleep Medicine · Richland, WANPI 1528163680

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $536 of the $671 with a category attached, or 79.9%. 8 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 50.3% of the total. That places this record below the midpoint for sleep medicine clinicians in WA, where the typical reported total is $748.

$671in general payments, 2019–2025

Across 24 payments — averaging $27.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$337
  • Harmony Biosciences LLC$171
  • Sunovion Pharmaceuticals Inc.$70
  • Vanda Pharmaceuticals Inc.$25
  • Axsome Therapeutics, Inc.$22
  • Lilly USA, LLC$20
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$53680%
  • Education$13520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$671 in reported general payments places this provider in the 45th percentile of 67 sleep medicine providers in Washington.

See all sleep medicine providers in Washington

Medicare billing

Part B allowed, 2024
$276,664
Medicare patients
711
Services billed
1,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant24$10,643
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine100$3,254
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl22$1,597
Trazodone Hcl165$1,371
Pramipexole DihydrochloridePramipexole Di-Hcl88$1,159
Quetiapine Fumarate65$1,113
Zolpidem Tartrate162$750
Doxepin Hcl13$512
Temazepam48$426
Olanzapine22$369
Eszopiclone24$344
Gabapentin30$335
Ropinirole Hcl13$295
Clonazepam25$179
Sertraline Hcl18$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$20$36922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 67 sleep medicine providers in Washington.

Other sleep medicine in Richland

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →